Oculis (NASDAQ:OCS) Sees Large Volume Increase - Still a Buy?

Oculis Holding AG (NASDAQ:OCS - Get Free Report) shares saw an uptick in trading volume on Friday . 24,743 shares changed hands during mid-day trading, a decline of 43% from the previous session's volume of 43,667 shares.The stock last traded at $17.97 and had previously closed at $17.89.

Analyst Ratings Changes

OCS has been the topic of a number of research analyst reports. Chardan Capital reissued a "buy" rating and issued a $28.00 target price on shares of Oculis in a research report on Thursday, April 17th. Robert W. Baird raised their target price on Oculis from $37.00 to $41.00 and gave the company an "outperform" rating in a report on Thursday, March 13th. Finally, HC Wainwright boosted their price target on shares of Oculis from $29.00 to $32.00 and gave the stock a "buy" rating in a research note on Thursday, April 17th.

Oculis Trading Down 1.5 %

The business has a fifty day moving average price of $18.31 and a 200 day moving average price of $18.19. The firm has a market cap of $755.35 million, a PE ratio of -8.96 and a beta of 0.19. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS - Get Free Report) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.28). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. Analysts forecast that Oculis Holding AG will post -2.09 EPS for the current year.

Institutional Investors Weigh In On Oculis

Several large investors have recently modified their holdings of the company. abrdn plc grew its stake in Oculis by 23.0% in the 4th quarter. abrdn plc now owns 1,009,424 shares of the company's stock valued at $17,150,000 after acquiring an additional 188,871 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Oculis by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after purchasing an additional 1,800 shares during the last quarter. XTX Topco Ltd purchased a new stake in Oculis in the 4th quarter valued at approximately $225,000. Bellevue Group AG purchased a new position in Oculis during the fourth quarter worth $170,000. Finally, Bank of America Corp DE increased its position in Oculis by 58.2% during the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock worth $493,000 after purchasing an additional 10,667 shares in the last quarter. 22.30% of the stock is owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.